Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 6/20 | 0.57 |
| ▸ | HTR1D | P28221 | 6/20 | 0.57 |
| ▸ | HTR1B | P28222 | 6/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15156267 | 0.88 | MEN1 (0.60) | GAAPOLBL3MBTL1TDP1MEN1 | |
| SCHEMBL3425520 | 0.86 | GAA (0.53) | GAAPOLBL3MBTL1TDP1MEN1 | |
| SCHEMBL15156731 | 0.85 | TPSAB1 (0.58) | GAAL3MBTL1MEN1KMT2ARECQL | |
| SCHEMBL528448 | 0.85 | ALDH1A1 (0.72) | POLBL3MBTL1KMT2ARECQLALDH1A1 | |
| SCHEMBL15156208 | 0.84 | GAA (0.51) | GAAPOLBL3MBTL1TDP1HTR1A | |
| SCHEMBL15156397 | 0.84 | ALDH1A1 (0.71) | GAAPOLBL3MBTL1TDP1HTR1A | |
| SCHEMBL15156212 | 0.83 | MEN1 (0.50) | GAAPOLBTDP1MEN1KMT2A | |
| SCHEMBL15134809 | 0.83 | GAA (0.76) | GAAPOLBL3MBTL1TDP1HTR1A | |
| SCHEMBL15134821 | 0.82 | GAA (0.74) | GAAPOLBL3MBTL1TDP1HTR1A | |
| SCHEMBL14578666 | 0.81 | L3MBTL1 (0.89) | GAAPOLBL3MBTL1TDP1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2809671-B1 | IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CEPHALON INC (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2809671-A1 | IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cephalon, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
| WO-2013116291-A1 | IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CEPHALON, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| EP-2597953-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | Inspire Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20130131059-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2012015760-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131059-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | ROCK1, ROCK2, CIT | GAA 1158/4885POLB 2588/4885L3MBTL1 4254/4885 |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | JAK1, ALK, JAK2 | GAA 2612/4885POLB 741/4885L3MBTL1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.